drugset
Drugs / MM120
last change Sep 2025 re-read 3 minutes ago

MM120

also known as d-Lysergic Acid Diethylamide (LSD) D-tartrate · LSD
Developed for
attention deficit-hyperactivity disorder · generalized anxiety disorder
Investigated by
Definium Therapeutics US, Inc.

Trials 2

today NCT05407064 · Ph 2 NCT05200936 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05407064 Aug 2022 → Oct 2023 generalized anxiety disorder Definium Therapeutics US, Inc. Completed Mixed
Phase 2 NCT05200936 Dec 2021 → Nov 2023 attention deficit-hyperactivity disorder Definium Therapeutics US, Inc. Completed Missed primary

Press releases naming this drug 10 releases

DateIssuerRelease
2025-09-04 Definium Therapeutics US, Inc. Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD) definiumtx.com ↗
2025-04-15 Definium Therapeutics US, Inc. MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) definiumtx.com ↗
2025-01-30 Definium Therapeutics US, Inc. MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder definiumtx.com ↗
2024-12-16 Definium Therapeutics US, Inc. MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) definiumtx.com ↗
2024-12-05 Definium Therapeutics US, Inc. MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD) definiumtx.com ↗
2024-07-17 Definium Therapeutics US, Inc. MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT) definiumtx.com ↗
2024-06-20 Definium Therapeutics US, Inc. MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) definiumtx.com ↗
2024-05-04 Definium Therapeutics US, Inc. MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York definiumtx.com ↗
2024-03-07 Definium Therapeutics US, Inc. MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder definiumtx.com ↗
2024-03-01 Definium Therapeutics US, Inc. MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120 definiumtx.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MM120 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05407064 ↗
1

NCT05200936 ↗
Known as d-Lysergic Acid Diethylamide (LSD) D-tartrate “d-Lysergic Acid Diethylamide (LSD) D-tartrate (MM120)” NCT05200936 ↗
Known as LSD “d-Lysergic Acid Diethylamide (LSD) D-tartrate (MM120)” NCT05200936 ↗
Action Activate “mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).” NCT05407064 ↗
Route Oral “20 μg of MM120 administered orally twice weekly for 6 weeks” NCT05200936 ↗